Consistent with STEP-HFpEF, targeting metabolic drivers with GLP-1 receptor agonists can benefit an obesity-related phenotype, whereas a congestion-dominant profile may prioritize SGLT2 inhibition and diuretics [122,222]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.